8 research outputs found
EffektivitĂ€t eines patientenzentrierten Stationssettings fĂŒr Demenzpatienten mit internistischen Erkrankungen:eine empirische Verlaufsstudie
Anhand empirischer Daten aus dem Jahre 1997 der Station Franziskus, Geriatrie-Zentrum Haus Berge, Elisabeth Krankenhaus Essen, wird diskutiert, welche Bedeutung einem patientenzentrierten, an die besonderen VerhÀltnisse dementer Patienten ausgerichteten Stations-Setting in der internistischen Diagnostik und Therapie zukommt. Nur die patientenorientierte Kooperation zwischen Geriatrie und Gerontopsychiatrie kann eine optimale Betreuung internistisch erkrankter Dementer bewirken. Unter paralleler Therapie von Demenz und internistischer Begleiterkrankung kommt es zu einer signifikanten Verbesserung der SelbststÀndigkeit in den AktivitÀten des tÀglichen Lebens (ADL). Eine klinisch relevante Besserung zeigte sich unter Festlegung eines Responderkriteriums bei 76.3 % der Betroffenen. Der Schweregrad der Demenz (gemÀà GDS) zeigte bei 64 % der Patienten eine Verbesserung unterschiedlicher AusprÀgung
Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia
Abstract Background Cancer cachexia is associated with reduced body weight, appetite and quality of life (QOL) with no approved treatments. Growth hormone secretagogues like macimorelin have potential to mitigate these effects. Methods This pilot study assessed the safety and efficacy of macimorelin for 1 week. Efficacy was defined a priori as 1âweek change in body weight (â„0.8 kg), plasma insulinâlike growth factor (IGF)â1 (â„50 ng/mL) or QOL (â„15%). Secondary outcomes included food intake, appetite, functional performance, energy expenditure and safety laboratory parameters. Patients with cancer cachexia were randomized to 0.5 or 1.0 mg/kg macimorelin or placebo; outcomes were assessed nonâparametrically. Results Participants receiving at least one of either macimorelin dose were combined (N = 10; 100% male; median age = 65.50 ± 2.12) and compared with placebo (N = 5; 80% male; median age = 68.00 ± 6.19). Efficacy criteria achieved: body weight (macimorelin N = 2; placebo N = 0; P = 0.92); IGFâ1 (macimorelin N = 0; placebo N = 0); QOL by Anderson Symptom Assessment Scale (macimorelin N = 4; placebo N = 1; P = 1.00) or Functional Assessment of Chronic Illness TherapyâFatigue (FACITâF; macimorelin N = 3; placebo N = 0; P = 0.50). No related serious or nonâserious adverse events were reported. In macimorelin recipients, change in FACITâF was directly associated with change in body weight (r = 0.92, P = 0.001), IGFâ1 (r = 0.80, P = 0.01), and caloric intake (r = 0.83, P = 0.005), and inversely associated with change in energy expenditure (r = â0.67, P = 0.05). Conclusions Daily oral macimorelin for 1 week was safe and numerically improved body weight and QOL in patients with cancer cachexia compared with placebo. Longer term administration should be evaluated for mitigation of cancerâinduced reductions in body weight, appetite and QOL in larger studies
Negishi cross-coupling of organotellurium compounds: synthesis of biaryls, aryl-, and diaryl acetylenes
Dynamics of thermographic skin temperature response during squat exercise at two different speeds
Mental Health Status, Life Satisfaction, and Mood State of Elite Athletes During the COVID-19 Pandemic: A Follow-Up Study in the Phases of Home Confinement, Reopening, and Semi-Lockdown Condition
Make EU trade with Brazil sustainable
Brazil, home to one of the planet's last great forests, is currently in trade negotiations with its second largest trading partner, the European Union (EU). We urge the EU to seize this critical opportunity to ensure that Brazil protects human rights and the environment